# OnCo record metastatic-anal-cancer (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/metastatic-anal-cancer/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "metastatic-anal-cancer" ;
  schema:name "Metastatic and recurrent anal squamous cell carcinoma"@en ;
  schema:alternateName "Advanced anal cancer"@en, "Stage IV anal squamous cell carcinoma"@en, "Inoperable recurrent anal cancer"@en, "Metastatic SCAC"@en ;
  schema:description "Metastatic anal cancer is squamous cell anal cancer that has spread to the liver, lungs or distant lymph nodes, or come back where surgery can no longer remove it. Carboplatin with paclitaxel became the standard first treatment after the InterAACT trial, the PD-1 antibody retifanlimab was added to it in 2025 after POD1UM-303, and nivolumab or pembrolizumab are options after chemotherapy."@en ;
  schema:url <https://onco.cc/cancers/metastatic-anal-cancer/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Anal_cancer> ;
  schema:citation <https://doi.org/10.1200/JCO.19.03266>, <https://doi.org/10.1016/S0140-6736(25)00631-2>, <https://en.wikipedia.org/wiki/Anal_cancer> ;
  onco:tag "subtype-page", "gastrointestinal" ;
  onco:related <https://onco.cc/cancers/localised-anal-cancer/>, <https://onco.cc/cancers/anal-hsil-precursor/>, <https://onco.cc/cancers/anal/>, <https://onco.cc/cancers/recurrent-metastatic-cervical-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/cthpv-dna/>, <https://onco.cc/technologies/sbrt/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/retifanlimab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/fluorouracil/> ;
  onco:terms <https://onco.cc/terms/hpv-p16/>, <https://onco.cc/terms/re-irradiation/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-interaact-anal-cancer-carboplatin-paclitaxel-jco-2020/>, <https://onco.cc/key-papers/paper-esmo-anal-cancer-guideline-ann-oncol-2021/> ;
  onco:pipeline <https://onco.cc/drugs/retifanlimab/>, <https://onco.cc/technologies/cthpv-dna/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:standardOfCare <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/retifanlimab/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/terms/re-irradiation/> .